Natco inks deal with Mabxience to manufacture mAb drugs Pharmaceutical Business Review Three of the four products including Trastuzumab, Bevacizumab, Rituximab belong to the oncology segment, while Etanercept is used to treat auto-immune disease. As per the terms of the agreement, Natco will manufacture drug products, undertake local ... |
